Secretory Phospholipase A 2 in Patients With Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain Episodes.
Rawan Korman, Maria Yasmine, Dunia Hatabah et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated plasma levels of secretory phospholipase A 2 (sPLA 2) in 105 pediatric patients with sickle cell disease hospitalized for vaso-occlusive pain episodes. The study found that 33% of patients had elevated sPLA 2 levels, with higher levels associated with acute chest syndrome. Arginine therapy significantly reduced sPLA 2 levels by discharge compared to placebo (-27.8 ng/mL vs -15.0 ng/mL; p = 0.002).
Key findings
- 33% of patients had elevated sPLA 2 levels, with a mean of 85.7 ± 32.9 ng/mL.
- sPLA 2 elevation was more common in patients with acute chest syndrome (64% vs 30%; p = 0.02).
- Peak sPLA 2 levels were significantly higher in febrile patients (101.0 ± 45.3 ng/mL) compared to afebrile patients (48.7 ± 35.4 ng/mL; p < 0.0001).
- Arginine therapy reduced sPLA 2 levels by discharge compared to placebo (-27.8 ± 38.1 ng/mL vs -15.0 ± 41.2 ng/mL; p = 0.002).
Why it matters
Understanding the role of sPLA 2 as a biomarker for acute chest syndrome in sickle cell disease can help clinicians identify at-risk patients and potentially guide treatment decisions, particularly regarding the use of arginine therapy.